ANRO logo

ANRO
Alto Neuroscience Inc.

1,108
Mkt Cap
$729.25M
Volume
263,926.00
52W High
$28.44
52W Low
$2.15
PE Ratio
-8.37
ANRO Fundamentals
Price
$21.54
Prev Close
$20.78
Open
$20.75
50D MA
$23.41
Beta
1.68
Avg. Volume
331,397.92
EPS (Annual)
-$2.19
P/B
2.99
Rev/Employee
$0.00
$361.04
Loading...
Loading...
News
all
press releases
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni...
Business Wire·6d ago
News Placeholder
More News
News Placeholder
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported...
Business Wire·8d ago
News Placeholder
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that...
Business Wire·10d ago
News Placeholder
Alto Neuroscience (ANRO) Projected to Post Earnings on Wednesday
Alto Neuroscience (NYSE:ANRO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat·15d ago
News Placeholder
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a...
Business Wire·17d ago
News Placeholder
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rati...
MarketBeat·27d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital
Chardan Capital reaffirmed a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Wednesday...
MarketBeat·29d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High - Still a Buy?
Alto Neuroscience (NYSE:ANRO) Sets New 52-Week High - Should You Buy...
MarketBeat·29d ago
News Placeholder
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Here's Why
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2% - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b...
Business Wire·1mo ago
<
1
2
...
>

Latest ANRO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.